WallStSmart

Ridgetech, Inc. (RDGT)vsScienture Holdings, Inc. (SCNX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Ridgetech, Inc. generates 25008% more annual revenue ($119.94M vs $477,680). RDGT leads profitability with a 10.3% profit margin vs 0.0%. RDGT earns a higher WallStSmart Score of 37/100 (F).

RDGT

Hold

37

out of 100

Grade: F

Growth: 2.7Profit: 5.0Value: 5.0Quality: 6.5
Piotroski: 4/9Altman Z: 1.41

SCNX

Avoid

33

out of 100

Grade: F

Growth: 5.3Profit: 2.5Value: 6.0Quality: 6.0
Piotroski: 4/9Altman Z: 0.19
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for RDGT.

SCNXUndervalued (+21.4%)

Margin of Safety

+21.4%

Fair Value

$0.57

Current Price

$0.36

$0.21 discount

UndervaluedFair: $0.57Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

RDGT3 strengths · Avg: 9.7/10
Price/BookValuation
0.0x10/10

Reasonable price relative to book value

Return on EquityProfitability
30.2%10/10

Every $100 of equity generates 30 in profit

Debt/EquityHealth
0.169/10

Conservative balance sheet, low leverage

SCNX3 strengths · Avg: 10.0/10
Price/BookValuation
0.2x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
449.1%10/10

Revenue surging 449.1% year-over-year

Debt/EquityHealth
0.0010/10

Conservative balance sheet, low leverage

Areas to Watch

RDGT4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.27M3/10

Smaller company, higher risk/reward

Revenue GrowthGrowth
-11.7%2/10

Revenue declined 11.7%

Altman Z-ScoreHealth
1.412/10

Distress zone — elevated risk

SCNX4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$14.33M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-0.1%2/10

ROE of -0.1% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : RDGT

The strongest argument for RDGT centers on Price/Book, Return on Equity, Debt/Equity.

Bull Case : SCNX

The strongest argument for SCNX centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 449.1% demonstrates continued momentum.

Bear Case : RDGT

The primary concerns for RDGT are EPS Growth, Market Cap, Revenue Growth.

Bear Case : SCNX

The primary concerns for SCNX are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

RDGT profiles as a declining stock while SCNX is a hypergrowth play — different risk/reward profiles.

SCNX is growing revenue faster at 449.1% — sustainability is the question.

RDGT generates stronger free cash flow (5M), providing more financial flexibility.

Monitor PHARMACEUTICAL RETAILERS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

RDGT scores higher overall (37/100 vs 33/100). SCNX offers better value entry with a 21.4% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Ridgetech, Inc.

HEALTHCARE · PHARMACEUTICAL RETAILERS · USA

China Jo-Jo Drugstores, Inc. is a retailer and wholesale distributor of pharmaceutical and other healthcare products in the People's Republic of China. The company is headquartered in Hangzhou, the People's Republic of China.

Visit Website →

Scienture Holdings, Inc.

HEALTHCARE · PHARMACEUTICAL RETAILERS · USA

Scienture Holdings, Inc. (SCNX) is a biotechnology firm focused on developing advanced therapeutic solutions for neurological disorders, utilizing an innovative drug development pipeline backed by a skilled research team. With a strong emphasis on addressing unmet medical needs, Scienture is poised to enhance patient outcomes while navigating the complexities of regulatory pathways. The company’s dedication to scientific rigor and its strategic partnerships not only bolster its growth potential but also position SCNX as a significant contributor to advancements in global healthcare. As the demand for effective neurological treatments grows, Scienture aims to leverage emerging opportunities within the expanding healthcare landscape.

Want to dig deeper into these stocks?